Sponsored by
Pretty exciting results for fourth line therapy. 55% disease control rate and median survival of 10 months after 4th recurrence. This was only a phase 1 trial. but it is proof of concept that the Car-T cells may work in brain cancer. Car-t cells have been a major breakthrough in other types of cancers but up until now hasn't shown much success in the brain.